S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Cara Therapeutics (CARA) Stock Forecast, Price & News

+0.23 (+2.87%)
(As of 05/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
282,002 shs
Average Volume
885,711 shs
Market Capitalization
$441.58 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CARA News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Cara Therapeutics logo

About Cara Therapeutics

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.


Cara Therapeutics Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$23.03 million
Book Value
$3.81 per share


Net Income
$-88.44 million
Pretax Margin




Free Float
Market Cap
$441.58 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.16 out of 5 stars

Medical Sector

421st out of 1,428 stocks

Pharmaceutical Preparations Industry

178th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions

Is Cara Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cara Therapeutics stock.
View analyst ratings for Cara Therapeutics
or view top-rated stocks.

Are investors shorting Cara Therapeutics?

Cara Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 5,350,000 shares, an increase of 30.2% from the April 30th total of 4,110,000 shares. Based on an average daily volume of 688,700 shares, the short-interest ratio is currently 7.8 days. Approximately 12.0% of the company's shares are sold short.
View Cara Therapeutics' Short Interest

When is Cara Therapeutics' next earnings date?

Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Cara Therapeutics

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) issued its quarterly earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.04. During the same period in the prior year, the firm posted ($0.47) earnings per share.
View Cara Therapeutics' earnings history

What price target have analysts set for CARA?

4 analysts have issued 1 year price objectives for Cara Therapeutics' shares. Their forecasts range from $20.00 to $30.00. On average, they expect Cara Therapeutics' stock price to reach $26.80 in the next twelve months. This suggests a possible upside of 225.2% from the stock's current price.
View analysts' price targets for Cara Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Cara Therapeutics' key executives?
Cara Therapeutics' management team includes the following people:
  • Mr. Christopher A. Posner, Pres, CEO & Director (Age 52, Pay $431.9k)
  • Dr. Derek T. Chalmers D.Sc., Ph.D., Co-Founder & Sr. Advisor (Age 58, Pay $580.93k)
  • Mr. Thomas Charles Reilly, Chief Financial Officer (Age 49, Pay $670.94k) (LinkedIn Profile)
  • Dr. Frédérique Menzaghi, Chief Scientific Officer and Sr. VP of R&D (Age 56, Pay $826.94k)
  • Mr. Scott M. Terrillion, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 59, Pay $689.63k) (LinkedIn Profile)
  • Dr. Joana Goncalves, Chief Medical Officer (Age 48, Pay $826.77k) (LinkedIn Profile)
  • Mr. Richard Makara, VP, Head of Accounting, Controller & Principal Accounting Officer (Age 51)
  • Mr. Eric Vandal, Sr. VP of Commercial
  • Ms. Beth Weinberg, Sr. VP of Regulatory Affairs & QA
What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), (CGC), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), (XXII), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.41%), Vanguard Group Inc. (6.05%), Farallon Capital Management LLC (4.67%), Disciplined Growth Investors Inc. MN (3.16%), State Street Corp (3.14%) and Chescapmanager LLC (2.19%). Company insiders that own Cara Therapeutics stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends for Cara Therapeutics

Which major investors are selling Cara Therapeutics stock?

CARA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Chescapmanager LLC, Charles Schwab Investment Management Inc., Davy Global Fund Management Ltd, Principal Financial Group Inc., JPMorgan Chase & Co., Jane Street Group LLC, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Cara Therapeutics company stock in the last year include Christopher Posner, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion, and Thomas Charles Reilly.
View insider buying and selling activity for Cara Therapeutics
or view top insider-selling stocks.

Which major investors are buying Cara Therapeutics stock?

CARA stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Pinnacle Associates Ltd., Dimensional Fund Advisors LP, Vanguard Group Inc., State Street Corp, Jupiter Asset Management Ltd., Royce & Associates LP, and Vident Investment Advisory LLC.
View insider buying and selling activity for Cara Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Cara Therapeutics?

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $8.24.

How much money does Cara Therapeutics make?

Cara Therapeutics has a market capitalization of $441.58 million and generates $23.03 million in revenue each year. The biopharmaceutical company earns $-88.44 million in net income (profit) each year or ($1.78) on an earnings per share basis.

How many employees does Cara Therapeutics have?

Cara Therapeutics employs 84 workers across the globe.

What is Cara Therapeutics' official website?

The official website for Cara Therapeutics is www.caratherapeutics.com.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at [email protected], or via fax at 203-567-1510.

This page was last updated on 5/29/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.